Alendronate in patients with calcium nephrolithiasis and loss of bone mass

• Authors: Miguel Arrabal-Polo , Miguel Arrabal-Martin , Salvador Arias-Santiago , Armando Zuluaga-Gomez
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Alendronate; Calcium stones; Bone density loss

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 4
• Pages: 429-434

Dates

published

1 - 8 - 2012

online

24 - 5 - 2012

Contributors

author

Miguel Arrabal-Polo

• Urology Department, San Cecilio University Hospital, 18003, Granada, Spain

author

Miguel Arrabal-Martin

• Urology Department, San Cecilio University Hospital, 18003, Granada, Spain

author

Salvador Arias-Santiago

• Medicine Department, Granada University, 18003, Granada, Spain

author

Armando Zuluaga-Gomez

• Urology Department, San Cecilio University Hospital, 18003, Granada, Spain

References

• [1] Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Study of the physical-chemical factors in patients with renal lithiasis. Arch Esp Urol. 2006; 59:583–594
• [2] Arrabal Martín M, Díaz de la Guardia FV, Jiménez Pacheco A, López León V, Arrabal Polo MA, Zuluaga Gómez A. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol. 2007; 60:745–754 http://dx.doi.org/10.4321/S0004-06142007000700004[Crossref]
• [3] Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009; 41:926–930 http://dx.doi.org/10.1038/ng.404[WoS][Crossref]
• [4] Cipriani Thorne E. Osteoporosis: Consideraciones diagnosticas y terapeuticas. Rev Med Hered. 2004; 15:101–107
• [5] Moro-Alvarez MJ, Cabrera JA. Osteoporosis in men. Rev Clin Esp. 2010; 210:342–349 http://dx.doi.org/10.1016/j.rce.2009.11.023[Crossref]
• [6] Morales Piga A. Advances in the treatment of osteoporosis at the beginning of the new millennium. Rev Clin Esp. 2002; 202:23–26 [Crossref][PubMed]
• [7] Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95:1555–1565 http://dx.doi.org/10.1210/jc.2009-1947[Crossref]
• [8] Adrover Rigo M, Juste Diez de Pinos JL, Tuset Creus M, Codina Jane C, Ribas Sala J. Revision clínica de la utilización de los bifosfonatos. Farm Hosp. 2000; 24:74–82
• [9] Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull. 2002; 49:1–18 [PubMed]
• [10] Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007; 23:1341–1349 http://dx.doi.org/10.1185/030079907X188035[WoS][Crossref]
• [11] Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24:237–244 [Crossref]
• [12] Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116–1125 http://dx.doi.org/10.1210/jc.86.3.1116[Crossref]
• [13] Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29:1548–1558 http://dx.doi.org/10.1016/j.clinthera.2007.08.008[WoS][Crossref]
• [14] Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010; 22:404–409 http://dx.doi.org/10.1097/BOR.0b013e32833ad677[WoS][Crossref]
• [15] Venkatanarasimha N, Miles G, Suresh P. Subtrochanteric femoral insufficiency fractures related to the use of long-term biphosphonates: a pictorial review. Emerg Radiol. 2010; 17:511–515 http://dx.doi.org/10.1007/s10140-010-0890-y[Crossref]
• [16] Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95:5258–5265 http://dx.doi.org/10.1210/jc.2010-1571[Crossref][WoS]
• [17] Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García-Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006; 68:956–959 http://dx.doi.org/10.1016/j.urology.2006.06.007[Crossref]
• [18] Sakhaee K, Maalouf N, Kumar R, Pasch A, Moe O. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011; 79:393–403 http://dx.doi.org/10.1038/ki.2010.473[WoS][Crossref]
• [19] Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine. 2004; 71:51–55 http://dx.doi.org/10.1016/j.jbspin.2003.09.009[Crossref]
• [20] Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999; 55:234–243 http://dx.doi.org/10.1046/j.1523-1755.1999.00247.x[Crossref]
• [21] Ruml LA, Dubois SK, Roberts ML, Pak CY. Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res. 1995; 10:655–662 http://dx.doi.org/10.1002/jbmr.5650100420[Crossref]
• [22] Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int. 2007; 71:808–815 http://dx.doi.org/10.1038/sj.ki.5002181[WoS][Crossref]
• [23] Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009; 24:1472–1477 http://dx.doi.org/10.1093/ndt/gfn690[Crossref]
• [24] Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol. 2002; 168:937–940 http://dx.doi.org/10.1016/S0022-5347(05)64546-6[Crossref]

Identifiers

DOI

10.2478/s11536-012-0014-z